Plain-English translation of NCT07310693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers have developed a tool called the CLOVER score that uses medical information to predict which patients with blood clots (deep vein thrombosis or pulmonary embolism) might have an undiagnosed cancer. This study tests whether the CLOVER score works well in real-world settings by following two groups of patients: one group from past medical records and one group being monitored going forward. The goal is to see if this tool can reliably help doctors identify patients who need extra screening for hidden cancers.
When patients develop blood clots, especially unexpectedly, cancer can sometimes be the hidden cause. Currently, doctors don't have a reliable way to quickly predict which clot patients are most likely to have undetected cancer. This trial exists to validate a new computer-based prediction tool that could help doctors identify high-risk patients earlier and recommend appropriate cancer screening.
You likely qualify if…
You likely don't qualify if…
If you join the prospective (forward-looking) part of this study starting in December 2025, you will undergo standard blood clot evaluation including blood tests, chest X-rays, and age-appropriate cancer screening—the same tests you'd normally receive. Researchers will calculate your CLOVER score using a web-based tool at the time of diagnosis. You'll then be monitored over the study period to see whether the score accurately predicted your cancer risk, with follow-up lasting up to 24 months.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
Spain